Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.69 |
| ▸ | RXRB | P28702 | 6/20 | 0.69 |
| ▸ | RXRG | P48443 | 1/20 | 0.62 |
| ▸ | BCL2 | P10415 | 1/20 | 0.62 |
| ▸ | DHODH | Q02127 | 2/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.59 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.59 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.59 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | RARA | P10276 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 1/20 | 0.54 |
| ▸ | RARG | P13631 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31331712 | 1.00 | RXRA (0.69) | RXRARXRBRXRGBCL2DHODH | |
| Benzoic Acid SCHEMBL28361078 | 0.92 | KMO (0.66) | RXRARXRBRXRGBCL2DHODH | |
| SCHEMBL18621851 | 0.89 | DHODH (0.69) | RXRARXRBRXRGBCL2DHODH | |
| SCHEMBL121813 | 0.86 | KMO (0.68) | RXRARXRBDHODHKMO | |
| SCHEMBL980736 | 0.86 | DHODH (0.55) | RXRARXRBRXRGDHODHHSD17B1 | |
| Terephthalic Acid SCHEMBL8103061 | 0.86 | SMN1; SMN2 (0.65) | RXRARXRBDHODHPOLBMAPT | |
| SCHEMBL16166011 | 0.86 | KMO (0.72) | RXRARXRBRXRGBCL2DHODH | |
| SCHEMBL30066684 | 0.86 | KMO (0.72) | RXRARXRBRXRGBCL2DHODH | |
| SCHEMBL6019106 | 0.85 | CNR2 (0.69) | RXRARXRBDHODHHSD17B1HSD17B2 | |
| SCHEMBL4428711 | 0.85 | MAPT (0.64) | RXRARXRBDHODHHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10287230-B2 | Selective aerobic oxidation of dimethylbiphenyls | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-05-14 | — | — | US | disclosed |
| WO-2019070943-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10081593-B2 | Alkyl aromatic hydroalkylation for the production of plasticizers | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180179141-A1 | SELECTIVE AEROBIC OXIDATION OF DIMETHYLBIPHENYLS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2018-06-28 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-6903091-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050075328-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1140072-B1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004010943-A2 | SUBSTITUTED BENZANILIDES AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1381370-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1140072-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030018024-A1 | Biphenyl vasopressin agonists | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2002083145-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1140072-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040239-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | RXRA 753/4885RXRB 785/4885RXRG 985/4885 |
| US-20180179141-A1 | SELECTIVE AEROBIC OXIDATION OF DIMETHYLBIPHENYLS | CYP1B1, MSMO1, CYP1A1 | RXRA 899/4885RXRB 353/4885RXRG 1003/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | RXRA 753/4885RXRB 785/4885RXRG 985/4885 |
| US-10287230-B2 | Selective aerobic oxidation of dimethylbiphenyls | CYP1B1, MSMO1, CYP1A1 | RXRA 899/4885RXRB 353/4885RXRG 1003/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | RXRA 378/4885RXRB 394/4885RXRG 384/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | RXRA 753/4885RXRB 785/4885RXRG 985/4885 |
| US-10081593-B2 | Alkyl aromatic hydroalkylation for the production of plasticizers | ALKBH3, AHR, ADH1A | RXRA 123/4885RXRB 215/4885RXRG 135/4885 |
| US-20030018024-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, AVPR1A | RXRA 2771/4885RXRB 2149/4885RXRG 2363/4885 |
| US-20050075328-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | RXRA 2666/4885RXRB 2126/4885RXRG 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.